While preliminary, research hints at the potential for PCSK9 inhibitors to enhance walking capacity and overall quality of life in PAD patients, possibly by retarding atherosclerotic progression and improving blood flow to the lower limbs (42). The gene discussed is PCSK9; the disease is peripheral arterial disease.